Financial Performance - In 2022, Nanjing Well Pharmaceutical Group achieved a net profit attributable to shareholders of 95.03 million RMB, a decrease of 6.26% compared to 2021[5]. - The company's total revenue for 2022 was approximately 1.11 billion RMB, reflecting a year-on-year increase of 6.59%[22]. - The net profit attributable to shareholders was CNY 95.03 million, a decrease of 6.26% compared to the previous year[33]. - The company reported a net profit of 92.06 million RMB after deducting non-recurring gains and losses, down 6.56% from the previous year[22]. - The company reported basic earnings per share of CNY 0.72, down 5.26% from CNY 0.76 in 2021[23]. - The diluted earnings per share also decreased to CNY 0.71, a decline of 6.58% from the previous year[23]. - The weighted average return on equity was 6.64%, down from 7.63% in 2021, reflecting a decrease of 0.99 percentage points[23]. - The gross profit margin decreased to 27.34%, down by 1.16 percentage points compared to the previous year[55]. - The company achieved a net profit of 300 million RMB, an increase of 20% compared to the previous year[123]. Assets and Liabilities - As of December 31, 2022, the total assets of the company reached approximately 2.14 billion RMB, marking a 16.11% increase from the previous year[22]. - The net assets attributable to shareholders at the end of 2022 were approximately 1.48 billion RMB, up 7.06% from 2021[22]. - The company's short-term borrowings increased by 110.55% to 360,453,327.94 CNY, primarily due to new bank loans[62]. - The total remuneration for the company's directors and senior management during the reporting period amounted to CNY 559.86 million, with no changes in shareholdings reported[122]. Cash Flow - The net cash flow from operating activities for 2022 was approximately 108.99 million RMB, a significant recovery from a negative cash flow in 2021[22]. - The company reported a net cash flow from operating activities of CNY 108,989,026.49, a significant improvement from a negative cash flow in the previous year[52]. - The cash and cash equivalents increased by 33,564,603.83 CNY, reversing a previous decline of 9,295,502.68 CNY[61]. Research and Development - In 2022, the company's R&D expenses amounted to 53.87 million yuan, representing a year-on-year increase of 29.93%, accounting for 4.85% of operating revenue[39]. - The company has 32 ongoing R&D projects, including 4 raw material drug projects, with 10 new projects initiated in 2022[39]. - The company is actively collaborating with pharmaceutical companies to accelerate the R&D of active pharmaceutical ingredients and formulations[36]. - The company has established a provincial-level engineering technology research center for water-soluble pharmaceutical excipients, enhancing its R&D capabilities[68]. - The company reported a significant increase of 201.80% in R&D investment for glycerol ester series products compared to the previous year[74]. Market and Sales - The sales volume of synthetic lubricating base oil increased by 7.42% year-on-year, while sales revenue grew by 1.30%[34]. - The sales volume of pharmaceutical excipients increased by 29.73% year-on-year, with sales revenue rising by 18.87%[35]. - The revenue from pharmaceutical excipients (non-injection) was CNY 197.29 million, with a gross profit margin of 38.04%[55]. - The revenue from the Northeast region was CNY 33.50 million, showing a significant increase of 91.79% year-on-year[55]. - The overseas revenue reached CNY 69.23 million, with a year-on-year increase of 55.91%[55]. Strategic Focus - The company is focusing on strategic emerging industries such as biotechnology and new energy as part of its long-term development plan[33]. - The company is focusing on the development of high-performance lubricants for electric vehicles, driven by the growing demand in the market[46]. - The company aims to enhance its product series in pharmaceutical excipients, focusing on high-standard injectable excipients to increase market share[106]. - The company intends to expand its market presence by optimizing product structures and enhancing customized services in both pharmaceutical excipients and synthetic lubricating oils[107]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements in its reports[6]. - The company faces risks related to product and technology development, including potential mismatches with market demands and regulatory challenges[112]. - The company faces risks related to the quality control of pharmaceutical excipients due to the increasing regulatory scrutiny and the need for continuous improvement in quality control systems as the business scales up[113]. - Environmental protection regulations are becoming stricter, and the company may need to invest more in compliance, potentially increasing operational costs and impacting financial performance[113]. Governance and Compliance - The company has established a governance structure compliant with relevant laws and regulations, ensuring proper operation of the shareholders' meeting, board of directors, and supervisory board[119]. - The company has a risk management system in place that enhances the effectiveness of internal control and management of subsidiaries[152]. - The company has established an internal control system that effectively promotes the steady implementation of its strategy and safeguards the interests of all shareholders[152]. - The company has not faced any penalties from securities regulatory authorities in the past three years[130]. Environmental Responsibility - The company invested CNY 9,123,400 in environmental protection during the reporting period[155]. - The company has implemented various pollution control facilities, with a waste gas treatment capacity of 30,000 m³/h for volatile organic compounds and other pollutants[159]. - The wastewater treatment capacity is 500 tons/day, utilizing multiple advanced processes including SBR and MBR technology[159]. - The company has installed online monitoring equipment for pollutant emissions, ensuring real-time compliance with environmental regulations[163].

Financial Performance - The company's operating revenue for Q1 2023 was ¥246,445,272.15, representing a decrease of 15.19% compared to the same period last year[3] - The net profit attributable to shareholders was ¥26,310,732.19, down by 4.43% year-on-year[3] - The basic earnings per share for the period was ¥0.20, reflecting a decline of 4.76% compared to the previous year[3] - Total operating revenue for Q1 2023 was CNY 246,445,272.15, a decrease of 15.2% compared to CNY 290,586,279.28 in Q1 2022[13] - Net profit for Q1 2023 was CNY 25,635,740.84, a decline of 4.2% from CNY 26,763,211.11 in Q1 2022[14] - The net profit attributable to the parent company for Q1 2023 was CNY 26,310,732.19, a decrease of 4.4% compared to CNY 27,529,731.11 in Q1 2022[15] - The total operating revenue from sales of goods and services in Q1 2023 was CNY 192,568,787.82, a decline of 9.4% from CNY 212,565,168.83 in Q1 2022[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,222,032,915.04, an increase of 3.92% from the end of the previous year[4] - Total assets as of March 31, 2023, were CNY 2,222,032,915.04, an increase from CNY 2,138,160,094.23 at the end of 2022, marking a growth of 3.9%[12] - Total liabilities increased to CNY 701,845,128.22 from CNY 655,756,145.87 at the end of 2022, representing a rise of 7%[12] - Non-current assets totaled CNY 1,695,214,247.90, up from CNY 1,667,874,751.61 at the end of 2022, indicating a growth of 1.6%[11] Cash Flow - The net cash flow from operating activities was negative at -¥12,432,495.15, indicating a significant decline in cash generation[3] - The net cash flow from operating activities for Q1 2023 was negative at CNY -12,432,495.15, compared to a positive CNY 9,037,458.54 in Q1 2022[18] - The company incurred a total cash outflow from operating activities of CNY 207,996,715.51 in Q1 2023, slightly higher than CNY 205,447,864.92 in Q1 2022[18] - The net cash outflow from investing activities for Q1 2023 was CNY -31,422,829.04, compared to CNY -8,785,815.73 in Q1 2022[19] - The company reported cash inflows from financing activities of CNY 125,600,000.00 in Q1 2023, an increase from CNY 115,370,000.00 in Q1 2022[19] - The company reported a net cash inflow from financing activities of CNY 72,635,872.05 in Q1 2023, compared to CNY 66,972,377.01 in Q1 2022[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,087[6] - The top shareholder, Wu Renrong, holds 13.67% of the shares, with 10,890,000 shares pledged[7] Operating Costs and Expenses - Total operating costs for Q1 2023 were CNY 214,807,670.05, down 16.6% from CNY 257,641,185.97 in Q1 2022[14] - The company reported R&D expenses of CNY 12,944,144.72 for Q1 2023, an increase of 19.3% compared to CNY 10,847,878.76 in Q1 2022[14] Inventory and Receivables - Cash and cash equivalents increased to CNY 128,322,164.94 as of March 31, 2023, compared to CNY 99,827,619.02 at the end of 2022, representing a growth of 28.5%[11] - Accounts receivable rose to CNY 152,574,670.50, slightly up from CNY 151,137,005.14 at the end of 2022, indicating a 1% increase[11] - Inventory increased to CNY 185,884,308.49, up from CNY 165,129,389.22 at the end of 2022, reflecting a growth of 12.5%[11] Borrowings - Long-term borrowings increased by 42.54%, attributed to new bank loans during the reporting period[5] Miscellaneous - The weighted average return on equity decreased by 0.21 percentage points to 1.76%[3] - The company did not report any net profit from the merged entity in the current or previous period[16]

证券代码：603351 证券简称：威尔药业 公告编号：2023-016 南京威尔药业集团股份有限公司关于 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 05 月 05 日 下午 14:00-15:00 召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 04 月 25 日至 05 月 04 日 16:00 前登录上证路演中心 网站首页点击"提问预征集"栏目或通过公司邮箱 wellyy@well-js.com 进行提 问。公司将在说明会上对投资者普遍关注的问题进行回答。 一、说明会类型 南京威尔药业集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日发布公司 2022 年度报告及 2023 年第一季度报告，为便于广大投资者更全面深 入地了解公司公司经营成果、财务状况，公司拟召开 2022 年度暨 2023 年第一季 度网上业绩说明会，针对 2022 年度及 2023 年第一季度的经营成果及 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥262,865,410.62, a decrease of 5.92% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2022 was ¥17,789,152.14, down 34.94% year-over-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,270,113.68, a decline of 38.46% compared to the previous year[3]. - The basic earnings per share for Q3 2022 was ¥0.13, reflecting a decrease of 38.10% year-over-year[4]. - The net profit for Q3 2022 was CNY 77,248,178.32, a decrease of 7.4% compared to CNY 83,384,566.77 in Q3 2021[18]. - The operating profit for Q3 2022 was CNY 88,142,528.77, down 21.9% from CNY 112,796,265.16 in Q3 2021[18]. - The total comprehensive income for Q3 2022 was CNY 77,248,178.32, down from CNY 83,384,566.77 in Q3 2021[19]. - Basic and diluted earnings per share for Q3 2022 were CNY 0.59, a decrease from CNY 0.64 in Q3 2021[19]. Revenue and Costs - Total revenue for the first three quarters of 2022 reached ¥850,975,692.57, an increase of 11.4% compared to ¥764,195,246.66 in the same period of 2021[17]. - Total operating costs for the first three quarters of 2022 were ¥764,101,966.80, up from ¥652,384,213.26 in 2021, reflecting a year-on-year increase of 17.1%[17]. Assets and Liabilities - The total assets as of September 30, 2022, amounted to ¥2,081,052,946.01, representing a 13.01% increase from the end of the previous year[4]. - The total assets of the company reached ¥2,081,052,946.01, up from ¥1,841,426,562.78 at the end of 2021, reflecting a growth of 13.0%[15]. - The company reported a significant increase in total liabilities to ¥618,779,501.63 as of September 30, 2022, compared to ¥456,012,175.77 at the end of 2021, representing a rise of 35.6%[14]. - The company’s total liabilities increased, with a significant rise in borrowings to CNY 360,870,000.00 in Q3 2022 from CNY 170,559,040.00 in Q3 2021[23]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥40,452,488.32[3]. - The cash flow from operating activities for the first three quarters of 2022 was CNY 40,452,488.32, a significant improvement from a negative cash flow of CNY -78,272,989.21 in the same period of 2021[22]. - The company reported a net cash outflow from investing activities of CNY -175,558,816.01 for the first three quarters of 2022, compared to CNY -20,337,564.19 in the same period of 2021[22]. - The cash and cash equivalents at the end of Q3 2022 were CNY 65,576,292.39, down from CNY 90,783,659.51 at the end of Q3 2021[23]. - The company's cash and cash equivalents as of September 30, 2022, were ¥65,576,292.39, slightly down from ¥66,263,015.19 at the end of 2021[12]. Shareholder Information - The top ten shareholders collectively hold 70.77% of the company's shares, with the largest shareholder holding 13.67%[9]. Expenses - The company reported a significant increase in management expenses, contributing to the decline in net profit[6]. - Research and development expenses for the first three quarters of 2022 were ¥36,992,312.72, slightly up from ¥34,926,014.04 in 2021, indicating a focus on innovation[17]. Government Support - The company received government subsidies amounting to ¥2,207,000.00 during the reporting period[6]. Accounts Receivable and Inventory - Accounts receivable increased to ¥148,418,923.32 as of September 30, 2022, compared to ¥120,214,744.95 at the end of 2021, representing a growth of 23.4%[12]. - Inventory levels rose to ¥170,594,791.16, up from ¥142,442,042.74 in 2021, indicating a year-on-year increase of 19.8%[13]. Borrowings - Short-term borrowings surged to ¥328,383,358.80 as of September 30, 2022, compared to ¥171,193,229.29 at the end of 2021, marking an increase of 91.9%[14].

Financial Performance - The company's operating revenue for the first half of 2022 was RMB 588,110,281.95, representing a 21.31% increase compared to RMB 484,789,805.14 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was RMB 60,762,416.76, which is a 7.55% increase from RMB 56,498,039.97 in the previous year[18]. - The net cash flow from operating activities was RMB 9,437,590.82, a significant improvement from a negative cash flow of RMB -56,032,897.92 in the same period last year, marking a 116.84% change[18]. - The total assets at the end of the reporting period were RMB 2,032,084,113.47, reflecting a 10.35% increase from RMB 1,841,426,562.78 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company increased to RMB 1,419,147,128.45, a 2.64% rise from RMB 1,382,705,623.96 at the end of the previous year[18]. - The basic earnings per share for the first half of 2022 was RMB 0.45, up 4.65% from RMB 0.43 in the same period last year[19]. - The weighted average return on net assets was 4.30%, slightly up from 4.28% in the previous year, indicating a marginal improvement[20]. Revenue and Sales Growth - Sales volume of synthetic lubricating base oil increased by 16.45% compared to the same period last year, with sales revenue growing by 16.22%[32]. - The sales volume of pharmaceutical excipients grew by 37.74% year-on-year, with sales revenue increasing by 32.13%[33]. - The company achieved a revenue of 588.11 million yuan in the first half of 2022, representing a year-on-year growth of 21.31%[31]. Research and Development - Research and development expenses rose by 20.63% to approximately ¥24.46 million, reflecting the company's commitment to innovation and increased investment in R&D[38]. - The company established a new application development center and a technology transformation platform of 1,600 square meters to enhance its R&D capabilities[36]. - The company has 16 ongoing projects in R&D, with 6 new projects initiated and 5 new products registered with the CDE[36]. Market and Industry Trends - The pharmaceutical industry is experiencing a shift towards domestic excipients due to rising prices and supply shortages of raw materials, leading to a reshaping of the industry[33]. - The company is focusing on expanding its market presence in response to the demand for COVID-19 related pharmaceutical excipients[33]. - The company is actively participating in the development of low-carbon emission technologies in response to national carbon neutrality goals, which presents new opportunities for synthetic lubricating base oil innovation[28]. Financial Position and Assets - The total liabilities rose to CNY 611,184,134.65 from CNY 456,012,175.77, which is an increase of approximately 34.0%[116]. - Total current assets increased to CNY 517,008,123.30 from CNY 464,691,328.94, representing a growth of approximately 11.5%[114]. - Cash and cash equivalents rose significantly to CNY 133,205,087.81, up from CNY 66,263,015.19, marking an increase of about 100.7%[114]. Risks and Challenges - The company has outlined potential risks in its management discussion, emphasizing the importance of investor awareness regarding future plans and strategies[7]. - The company faces risks related to product and technology development, particularly in meeting safety and regulatory standards for pharmaceutical excipients[47]. - Fluctuations in the prices of key raw materials, such as ethylene oxide and propylene oxide, could impact production costs and overall financial performance[48]. Shareholder and Governance - The company has not proposed any profit distribution or capital reserve transfer for the half-year period[53]. - The controlling shareholders committed to a 36-month lock-up period for their shares post-IPO, with an automatic extension of 6 months if the stock price falls below the issue price for 20 consecutive trading days within the first 6 months[67]. - The company has established strict compliance with relevant laws and regulations regarding shareholding and transfer[75]. Environmental and Compliance - The company has established an environmental management system certified by ISO 14001, ensuring compliance with local environmental standards[63]. - The company's subsidiary, Weir Bio-Tech, is classified as a key pollutant discharge unit, with no exceedance of pollutant discharge limits reported during the reporting period[57]. - Weir Bio-Tech has implemented various pollution control facilities, with treatment capacities ranging from 1,000 m³/h to 30,000 m³/h, all operating normally[58][59].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 290,586,279.28, representing a year-on-year increase of 27.77%[4] - The net profit attributable to shareholders for the same period was CNY 27,529,731.11, reflecting a growth of 5.04% compared to the previous year[4] - Total operating revenue for Q1 2022 was CNY 290,586,279.28, an increase of 27.8% compared to CNY 227,430,578.90 in Q1 2021[16] - Net profit for Q1 2022 was CNY 26,763,211.11, slightly up from CNY 26,209,240.14 in Q1 2021, reflecting a growth of 2.1%[17] - The net profit attributable to the parent company for Q1 2022 was CNY 27,529,731.11, an increase from CNY 26,209,240.14 in Q1 2021, representing a growth of approximately 5%[18] - The company reported a total comprehensive income of CNY 26,763,211.11 for Q1 2022, compared to CNY 26,209,240.14 in Q1 2021, indicating a growth of approximately 2.1%[18] Earnings and Shareholder Returns - The basic earnings per share for Q1 2022 was CNY 0.21, up by 5.00% year-on-year[4] - The basic and diluted earnings per share for Q1 2022 were both CNY 0.21, compared to CNY 0.20 in the same period last year, indicating a 5% increase[19] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 1,948,551,368.50, which is a 5.82% increase from the end of the previous year[5] - Total assets reached CNY 1,948,551,368.50 as of March 31, 2022, up from CNY 1,841,426,562.78 at the end of 2021, indicating a growth of 5.8%[14] - Total liabilities increased to CNY 526,057,783.36 from CNY 456,012,175.77, reflecting a rise of 15.3%[14] Cash Flow - Cash flow from operating activities showed a net increase of 134.47% due to higher sales revenue[7] - Cash inflow from operating activities for Q1 2022 was CNY 214,485,323.46, up from CNY 139,927,816.64 in Q1 2021, marking a growth of about 53%[19] - The net cash flow from operating activities for Q1 2022 was CNY 9,037,458.54, a significant improvement from a net outflow of CNY 26,216,473.71 in Q1 2021[19] - Cash inflow from financing activities in Q1 2022 was CNY 115,370,000.00, compared to CNY 61,688,970.93 in Q1 2021, reflecting an increase of approximately 87%[20] - The net cash flow from financing activities for Q1 2022 was CNY 66,972,377.01, up from CNY 53,605,980.77 in Q1 2021, showing an increase of about 25%[20] - The total cash and cash equivalents at the end of Q1 2022 amounted to CNY 133,470,273.95, down from CNY 150,064,013.89 at the end of Q1 2021[20] Investment Activities - The company reported a net cash outflow from investing activities of -118.68%, primarily due to reduced project payments[7] - The cash outflow from investing activities for Q1 2022 was CNY 37,367,093.75, compared to CNY 133,876,080.15 in Q1 2021, showing a decrease of about 72%[20] - The company received CNY 28,581,278.02 from investment activities in Q1 2022, a decrease from CNY 180,910,415.47 in Q1 2021, reflecting a decline of approximately 84%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,417[9] Research and Development - Research and development expenses for Q1 2022 were CNY 10,847,878.76, compared to CNY 9,498,113.15 in Q1 2021, showing a growth of 14.2%[17] Financial Expenses - The company reported a decrease in financial expenses, which were CNY 2,418,434.28 in Q1 2022, down from CNY 929,220.95 in Q1 2021[17] Inventory and Receivables - Inventory as of March 31, 2022, was CNY 161,128,048.87, an increase of 13.1% from CNY 142,442,042.74 at the end of 2021[12] - The accounts receivable financing decreased by 70.38%, attributed to bank acceptance discounts and endorsements[7] - Short-term borrowings rose to CNY 252,329,771.89 from CNY 171,193,229.29, marking a 47.5% increase[13] - The company's short-term borrowings increased by 47.39% during the reporting period[7]

Financial Performance - In 2021, the company achieved a revenue of CNY 1,042,305,915.97, representing a 41.61% increase compared to CNY 736,063,748.91 in 2020[20]. - The net profit attributable to shareholders of the listed company for 2021 was CNY 101,370,204.55, a slight increase of 0.92% from CNY 100,446,704.13 in 2020[20]. - The net profit after deducting non-recurring gains and losses was CNY 98,518,949.74, which is a 12.52% increase from CNY 87,553,103.43 in 2020[20]. - The company's total assets as of the end of 2021 were CNY 1,841,426,562.78, reflecting a 12.53% increase from CNY 1,636,416,118.84 at the end of 2020[21]. - The net assets attributable to shareholders of the listed company increased by 6.39% to CNY 1,382,705,623.96 at the end of 2021, compared to CNY 1,299,661,888.92 at the end of 2020[21]. - The company achieved operating revenue of 1,042.31 million RMB in 2021, representing a year-on-year increase of 41.61%[29]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was 98.52 million RMB, up 12.52% compared to the previous year[29]. - The company reported a negative cash flow from operating activities of CNY -11,536,768.28 in 2021, a significant decrease from CNY 93,304,352.91 in 2020, indicating a 112.36% decline[20]. - The weighted average return on equity decreased by 0.30 percentage points to 7.63% in 2021[22]. - The basic earnings per share for 2021 was 0.76 RMB, unchanged from the previous year[22]. Research and Development - Research and development expenses amounted to CNY 41,459,191.08, up 13.32% compared to the previous year, accounting for 3.98% of total revenue[33][44]. - The company has 38 ongoing projects, with 18 newly initiated projects and 9 projects successfully completed during the reporting period[32]. - The company has established a new research center of 8,000 square meters, enhancing its technical development capabilities[32]. - The company is focusing on innovation in synthetic lubricating base oils to meet the growing demand in the automotive and refrigeration industries[40][41]. - The company emphasizes R&D innovation, maintaining a high level of investment to ensure competitive advantage[68]. - The company has established a provincial-level technology center and a provincial-level engineering research center for water-soluble pharmaceutical excipients[83]. - The company has collaborated with well-known domestic universities and research institutions to enhance its R&D capabilities[83]. - The company has initiated several new R&D projects, including the development of a new generation of polyol ester series products with an investment of 1,934,204.48 RMB[87]. Market and Sales Performance - Sales volume of synthetic lubricating base oil increased by 26.72% year-on-year, with sales revenue growing by 55.59%[30]. - The sales volume of pharmaceutical excipients grew by 7.24% year-on-year, with sales revenue increasing by 17.88%[31]. - The company expanded its overseas market presence, particularly in synthetic lubricating base oils, amid rising domestic demand[30]. - The company’s revenue from synthetic lubricating base oil reached CNY 73,707.75 million, with a year-on-year increase of 55.59%[78]. - Domestic sales accounted for CNY 69,551.76 million, reflecting a growth of 35.84% year-on-year[79]. - The company is investing heavily in R&D, allocating 10% of its revenue to develop new products and technologies, focusing on innovative drug formulations[118]. Financial Management and Risks - The company has outlined potential risks in its management discussion and analysis section, emphasizing the importance of investor awareness regarding these risks[7]. - The company faces challenges from global supply chain issues and extreme weather, impacting production and operations[29]. - The company faces risks from external factors such as rising raw material prices and inflationary pressures, which may impact profit margins[106]. - The company relies heavily on ethylene oxide and propylene oxide as key raw materials, and any supply disruptions or price volatility could directly impact production and financial performance[109]. - Environmental regulations are becoming stricter, and increased compliance costs could affect the company's operational performance if higher environmental standards are imposed[110]. Corporate Governance and Management - The company has received a standard unqualified audit report from its accounting firm, ensuring the accuracy and completeness of its financial statements[8]. - The company has a structured salary management system that includes fixed and performance-based compensation, aimed at motivating employees and ensuring sustainable development[135]. - The company emphasizes talent development through annual training plans, combining internal and external training to enhance employee skills and management capabilities[136]. - The company has a comprehensive remuneration structure for senior management, including a base salary and performance-based incentives[122]. - The company has established a joint venture, Nanjing Xingwei Biotechnology Co., Ltd., with a registered capital of RMB 50 million, where the company contributed RMB 25.5 million, accounting for 51%[193]. Shareholder and Equity Management - The company plans to distribute a cash dividend of CNY 3.00 per 10 shares, totaling CNY 40,643,529.60, subject to approval at the annual general meeting[5]. - The total number of shares held by the company's directors and senior management at the end of the reporting period was 64,087,939, a decrease of 1,029,000 shares compared to the beginning of the year[116]. - The company has committed to a 36-month lock-up period for major shareholders following the IPO, with automatic extensions under certain conditions[158]. - The company will use at least 20% of the previous year's audited net profit for share repurchase actions aimed at stabilizing the stock price[172]. - The company will ensure compliance with relevant laws and regulations regarding share repurchase and stock price stabilization measures[172]. Environmental and Social Responsibility - The environmental protection subsidiary, Weir Bio-Tech, did not exceed pollutant discharge limits during the reporting period[148]. - The company has established an emergency response plan for environmental incidents, which was revised in September 2021 and filed with the local emergency management bureau[152]. - The company has passed the ISO14001 environmental management system certification, ensuring compliance with local environmental standards[154]. - There were no administrative penalties due to environmental issues during the reporting period[155].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 南京威尔药业集团股份有限公司 2021 年第三季度报告 证券代码：603351 证券简称：威尔药业 南京威尔药业集团股份有限公司 2021 年第三季度报告 | 项目 | 本报告期金额 | 年初至报告期末金额 | 说明 | | --- | --- | --- | --- | | 非流动性资产处置损益（包括已 | -63,071.43 | -181,511.59 | | | 计提资产减值准备的冲销部分） | | | | | 计入当期损益的政府补助（与公 | | | | | 司正常经营业务密切相关，符合 | | | | | 国家政策规定、按照一定标准定 | 500,0 ...

Financial Performance - The company's operating revenue for the first half of 2021 was approximately RMB 484.79 million, representing a 45.90% increase compared to RMB 332.27 million in the same period last year[18]. - The net profit attributable to shareholders of the listed company was approximately RMB 56.50 million, a slight decrease of 1.66% from RMB 57.45 million in the previous year[18]. - The total profit for the same period was 75.99 million yuan, reflecting a year-on-year growth of 12.04%[28]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was 55.66 million yuan, up 5.75% year-on-year[28]. - The basic earnings per share for the first half of 2021 was RMB 0.43, a decrease of 2.27% compared to RMB 0.44 in the same period last year[19]. - The weighted average return on net assets was 4.28%, a decrease of 0.27 percentage points from 4.55% in the previous year[20]. Cash Flow and Financial Position - The net cash flow from operating activities was negative at approximately RMB -56.03 million, a significant decline of 205.73% compared to RMB 52.99 million in the same period last year[18]. - The total assets at the end of the reporting period were approximately RMB 1.68 billion, an increase of 2.90% from RMB 1.64 billion at the end of the previous year[18]. - The total liabilities reached CNY 365,979,084.97, compared to CNY 336,754,229.92, marking an increase of approximately 8.7%[111]. - The total equity attributable to shareholders increased to CNY 1,317,824,458.57 from CNY 1,299,661,888.92, showing a growth of about 1.7%[111]. - The cash and cash equivalents were RMB 71,575,075.68, down from RMB 75,558,517.87, indicating a decrease of about 5.2%[109]. Research and Development - The company invested 20.27 million yuan in R&D, accounting for 4.18% of its operating revenue[32]. - The company is focusing on developing new products and technologies to meet the needs of the pharmaceutical market, particularly in response to the pandemic[31]. - The company has established an independent research institute and is collaborating with a national key laboratory to enhance its R&D capabilities[32]. Market and Sales Performance - Sales volume of synthetic lubricating base oil increased by 29.53% compared to the same period last year, with sales revenue growing by 62.28%[28]. - Sales volume of pharmaceutical excipients grew by 2.31%, while sales revenue increased by 20.16% year-on-year[31]. - The company anticipates significant market opportunities in the pharmaceutical excipients sector, driven by increasing industry standards and consolidation trends[44]. Risks and Challenges - The company faces risks from external factors such as unstable global supply chains and fluctuating raw material prices, which may impact production costs and profit margins[45]. - The company faces significant risks in product and technology development due to the gap in product and service levels compared to advanced countries, which may adversely affect operational performance if R&D fails or products do not gain market acceptance[46]. - Quality control of pharmaceutical excipients is critical as it directly impacts drug safety and efficacy; failure to maintain quality control could lead to negative operational impacts[46]. Environmental Compliance - The company has maintained compliance with environmental protection regulations, with no major safety or environmental incidents reported during the period[33]. - The company has implemented pollution control measures and has reported no exceedances in pollutant discharge during the reporting period, indicating compliance with environmental regulations[55]. - The company is actively engaged in environmental impact assessments for its projects, ensuring compliance with local environmental regulations[58]. Shareholder and Stock Information - The total number of ordinary shareholders as of the end of the reporting period is 10,689[98]. - The largest shareholder, Wu Renrong, holds 18,521,981 shares, representing 14.17% of the total shares, with 9,820,000 shares pledged[100]. - The company has committed to not transferring shares for 12 months post-IPO for certain senior management personnel[71]. Accounting and Financial Reporting - The financial statements are prepared based on the assumption of going concern, with no significant doubts regarding the company's ability to continue operations[149]. - The company adheres to the accounting policies and estimates as per the Ministry of Finance's guidelines, ensuring accurate financial reporting[150]. - The company recognizes impairment losses when expected credit losses exceed the current carrying amount of the impairment provision for contract assets[187].

中国 南京 南京威尔药业集团股份有限公司 2021 年第一季度报告 公司代码：603351 公司简称：威尔药业 南京威尔药业集团股份有限公司 2021 年第一季度报告 二〇二一年四月 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度 末增减(%) | | | --- | --- | --- | --- | --- | | 总资产 | 1,692,772,461.39 | 1,636,416,118.84 | | 3.44 | | 归属于上市公司股东 | 1,326,308,127.61 | 1,299,661,888.92 | | 2.05 | | 的净资产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | 经营活动产生的现金 | -26,216,473.71 | 20,698,657.55 | | -226.66 | | 流量净额 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减（%） | | | 营业收入 | 227,430,578.90 | 155,40 ...